IGF-1 · DOSSIER

IGF-1

Insulin-like Growth Factor 1 · Somatomedin C · Peptide · 70 AS
LEGAL DE · PRESCRIPTION-ONLYEVIDENCE · EARLY CLINICAL STUDIES3 STUDIESWADA · S2
FIG.01 — SIGNAL CHAIN
GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA · ~7648.6 Da
02

Mechanism of action

What IGF-1 does in the body — step by step.

01

IGF-1 is a 70-amino-acid polypeptide with structural homology to insulin.

02

It binds primarily to the IGF-1 receptor (IGF-1R), through which it activates the PI3K/Akt/mTOR and Ras/MAPK signalling cascades.

03

Its main site of production is the liver, where synthesis is stimulated by growth hormone (GH).

03

Research status

How far along is the evidence?

PRECLINICALEARLY CLINICAL STUDIESCLINICALLY ESTABLISHED
The clinically best studied application of recombinant IGF-1 (mecasermin) is severe primary IGF-1 deficiency (IGFD) in children.
The clinically best studied application of recombinant IGF-1 (mecasermin) is severe primary IGF-1 deficiency (IGFD) in children.
For this indication, mecasermin (Increlex) has been approved in the EU and the USA since 2007.
In addition, IGF-1 has been investigated in clinical studies for ALS (amyotrophic lateral sclerosis); results were inconsistent.
In preclinical models, effects on skeletal muscle, bone density and peripheral nerve regeneration have been described.
Use outside approved indications — particularly for performance enhancement — is not clinically substantiated and carries considerable risks.
04

Known risks

Without human data, safety statements are limited. What is known:

01
Hypoglycaemia: the most clinically significant side effect, also described under therapeutic use
02
Acromegaly-like symptoms with overdose: bone growth, organ enlargement
03
Potentially proliferative effect on tumour tissue — oncological risk discussed in the literature
04
Hypotension, tachycardia, headache with too-rapid absorption
05
Increased intracranial pressure described in isolated cases
06
No safety data for non-medical use scenarios
05

Cited studies

Chronological — links lead to the source.

1997
Recombinant human insulin-like growth factor I for ALS: a randomized phase IIb/III study
PubMed 9063745 →
2008
Mecasermin (recombinant human insulin-like growth factor I) for the long-term treatment of growth failure in children with severe primary IGF-I deficiency
PubMed 18698613 →
2020
Insulin-like growth factor-I and its binding proteins: A review of their roles in growth and metabolism
PubMed 32312628 →
06

Frequently asked questions

What is IGF-1?+

IGF-1 is a 70-amino-acid polypeptide with structural homology to insulin.

What type of peptide is IGF-1?+

IGF-1 belongs to the IGF / insulin analog class.

What is IGF-1 used for?+

In research, IGF-1 has primarily been investigated in the context of: Muscle growth, Recovery. These are research findings (evidence: early clinical studies), not proven benefits in humans and not a usage recommendation.

Is IGF-1 legal in Germany?+

IGF-1 is prescription-only in Germany and may only be obtained with a medical prescription.

Is IGF-1 FDA-approved / legal in the US?+

The FDA status of IGF-1 is not clearly classified.

Is IGF-1 legal in Canada?+

The regulatory status of IGF-1 in Canada is not clearly classified.

Where can I buy IGF-1?+

Peptica sells nothing and names no sources. IGF-1 is "prescription-only" in Germany; obtaining unapproved substances outside clinical studies is illegal and carries quality and safety risks.

What is the dosage of IGF-1?+

Peptica publishes no dosing. IGF-1 is a prescription medicine — any dosing is determined individually by a physician. This is not medical advice.

Is IGF-1 banned in sport (WADA)?+

Yes. IGF-1 is on the WADA Prohibited List and is therefore banned in competitive sport.

What are the known risks of IGF-1?+

Documented risks include: Hypoglycaemia: the most clinically significant side effect, also described under therapeutic use; Acromegaly-like symptoms with overdose: bone growth, organ enlargement. This is not a complete safety assessment and not medical advice — see the risks section for the full list.

How well researched is IGF-1?+

The evidence is classified as “early clinical studies”. 3 studies are cited on this page.

What is the molecular weight of IGF-1?+

IGF-1 has a molar mass of about 7648.6 Da, with a plasma half-life of ~12–15 hours (protein-bound).

Which peptides are related to IGF-1?+

Closely related entries: CJC-1295, Ipamorelin, IGF-1 LR3. A direct side-by-side comparison is available via the compare function.

07

Dossier

Legal · Structure · Sources.

LEGAL STATUS BY REGION
Germanyprescription-only

Mecasermin (Increlex) is approved as a medicine in the EU for severe primary IGF-1 deficiency and is prescription-only. Use outside this indication — particularly as a performance-enhancing drug — is not permitted. IGF-1 is listed on the WADA Prohibited List (section S2). Unapproved sources (research chemical) are subject to the German Medicines Act (AMG) and are legally problematic.

Legal status varies by country and can change. This is not legal advice.

STRUCTURE & MOLECULE
H₂NGPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSACOOH
70
AMINO ACIDS
~7648.6
MOL. WEIGHT (Da)
~12–15 hours (protein-bound)
HALF-LIFE
SOURCES & EXTERNAL DATABASES

Methodology: Peptica compiles publicly available studies and regulatory information and assigns each statement an evidence level. Not medical advice. No warranty.

RELATED PEPTIDES & FURTHER READING
08

Community notes

Note: These posts are user opinions and not medical advice. Posts containing dosages, therapeutic claims or purchase recommendations are removed. All entries are manually reviewed before publication.
This page is intended solely for factual, scientifically oriented information. No medical advice · no dosage or usage recommendations · no claims of efficacy · no substitute for medical consultation. Peptica sells no substances. Partner links are marked as advertising; Peptica may earn a commission. © 2026 Peptica · Issue 01